Form 8-K - Current report:
SEC Accession No. 0001213900-24-097018
Filing Date
2024-11-13
Accepted
2024-11-12 19:36:04
Documents
15
Period of Report
2024-11-08
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220976-8k_klotho.htm   iXBRL 8-K 29824
2 TERMINATION AGREEMENT ea022097601ex10-1_klotho.htm EX-10.1 16027
  Complete submission text file 0001213900-24-097018.txt   267190

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kltow-20241108.xsd EX-101.SCH 3502
4 XBRL DEFINITION FILE kltow-20241108_def.xml EX-101.DEF 26521
5 XBRL LABEL FILE kltow-20241108_lab.xml EX-101.LAB 36430
6 XBRL PRESENTATION FILE kltow-20241108_pre.xml EX-101.PRE 25145
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0220976-8k_klotho_htm.xml XML 5485
Mailing Address 1115 BROADWAY 12TH FLOOR NEW YORK NY 10010
Business Address 1115 BROADWAY 12TH FLOOR NEW YORK NY 10010 646-916-5315
Klotho Neurosciences, Inc. (Filer) CIK: 0001907223 (see all company filings)

EIN.: 862727441 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41340 | Film No.: 241450659
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)